Survival
LIVER METASTASIS
In cohort 1, 34 (85.0%) of 40 patients had discontinued the treatment by the cutoff date, and 6 (15.0%) patients remained on treatment (Fig. In cohort 2, 31 (97%) of the 32 patients had dropped out, and 1 (3%) was still on treatment (Fig. Exploratory subgroup analysis of the full analysis set for cohorts 1 and 2 showed that the patients with liver metastasis had a similar ORR compared with the patients without. Patients who had previously been treated with EGFR inhibitors had a higher ORR than those who had not been treated with EGFR inhibitors in both cohort 1 (72.7% vs 62.1%) and cohort 2 (57.1% vs 24.0%). A higher ORR was also observed in patients with EBV DNA titers <10,000 copies/ml than in patients with >10,000 copies/ml in both cohort (73.1% vs 50.0%)1 and cohort 2(42.9% vs 18.2%). But the difference was not statistically significant (